24小时热门版块排行榜

返回列表

当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

lyman829

木虫 (正式写手)

应助: 19 (小学生)
金币: 3505.3
散金: 10
帖子: 437
在线: 1178.7小时
虫号: 470061
注册: 2007-11-29
性别: GG
专业: 合成药物化学

[交流] 【讨论】关于俄罗斯今年上市的一个新药已有7人参与

今年三月份，俄罗斯上市了一个抗流感的新药，商品名是ingavirin,俄语叫Ингавирин，但是居然找不到任何资料有结构报道，不知道各位对于这个药有什么高见，如能找到结构式就最好了

回复此楼

» 猜你喜欢

CSC改派-博士生交流访学已经有19人回复
中山大学-第七医院-招科研助理1名（基因设计和克隆、RNA合成）已经有0人回复
药物学论文润色/翻译怎么收费? 已经有70人回复
中山大学-第七医院-招科研助理1名（基因设计和克隆、RNA合成）已经有1人回复
巴黎萨克雷大学与国家留学基金委合作博士研究生项目-脂质纳米药物/生物材料/多酚递送已经有10人回复
中国药科大学2026入学博士，药物合成和设计经验，放射化学及放射医学研究已经有25人回复
26年申博——已发SCI6篇已经有13人回复
碱缸的配制已经有5人回复
新！澳门科技大学诚招2026年秋季药剂学/生物材料方向博士研究生（申请-考核制）已经有18人回复
澳科大药学院诚招2026年秋季纳米医学/生物材料博士研究生已经有15人回复

1楼 2009-08-12 22:55:24

已阅回复此楼关注TA 给TA发消息送TA红花 TA的回帖

maitians

铁杆木虫 (著名写手)

应助: 8 (幼儿园)
金币: 5907.8
红花: 56
帖子: 1399
在线: 280.8小时
虫号: 817018
注册: 2009-07-27
专业: 有机合成

★
小木虫(金币+0.5):给个红包，谢谢回帖交流

Ingavirin® - drug destined for new direction in the flu therapy

Three months ago one of the largest Russian pharmaceutical company Valenta have launched new antiviral product.

Ingavirin® – original innovative domestic product developed by Russian scientists including military virologists under supervision of the Chief Therapist of Russian Federation, Academician of RAS Alexander G. Chuchalin.

Product was registered in August, 2008 and was presented in the market in January 2009. Registration certificate LSR  – 006330/08.

   High antiviral efficacy was showed in the trials in vitro and in vivo to the A grippe (subtypes H3N2, H1N1, H5N1), experimental  B virus, adenoviruses.
   Ingavirin® suppresses virus replication in the nuclear stage of the cycle. Antiviral efficacy of Ingavirin® to A virus is realized by the inhibition of the newly synthesized viral NP-protein migration from cytoplasm to nucleus, which is necessary for the infectious process in the  infected cells.
In distinction from the existing products aimed for the flu treatment Ingavirin is operating to the new protein target - NP-protein. Ingavirin is the only antiviral product providing cell protection by the abruption of the virus multiplication. Expectancy of the resistance evolution is extremely small.
   Clinical trials of Ingavirin® within I, II, III phases of trials were fulfilled in the specialized research centers of Russia under guidance of Professor of the Ivanovsky Scientific Institute of Virology Kolobukhina L.V. High curative efficacy and safety was proven.